Semaglutide Dosing Protocol: STEP Trial Reference for Researchers

Semaglutide's clinical dosing framework was established across the STEP (Semaglutide Treatment Effect in People with Obesity) programme. STEP 1, published in the New England Journal of Medicine in 2021 (doi:10.1056/NEJMoa2032183), used a once-weekly subcutaneous injection escalation from 0.25mg to a 2.4mg maintenance dose over 16 weeks, followed by 52 weeks at maintenance. Total trial duration was 68 weeks.

The slow escalation schedule was designed to allow gastrointestinal tolerability to develop gradually — nausea, vomiting, and diarrhoea are the most common adverse effects of GLP-1 receptor agonism and are substantially attenuated by graduated dose increases. STEP 1 enrolled 1,961 adults and demonstrated a mean body weight reduction of 14.9% from baseline at week 68 in the Semaglutide arm versus 2.4% in placebo.

This article summarises the published trial dosing protocol as a reference for researchers. All information presented is derived from publicly available clinical literature. Semaglutide supplied by RetaLABS is for laboratory research use only — not for human consumption.

The STEP 1 trial escalation proceeded as follows, with dose increases every four weeks:

Weeks	Weekly Dose	Phase
1–4	0.25 mg	Initiation
5–8	0.5 mg	Escalation
9–12	1.0 mg	Escalation
13–16	1.7 mg	Escalation
17–68	2.4 mg	Maintenance

The protocol permitted participants to remain at a lower dose for an additional 4 weeks if tolerability was insufficient for escalation. In research settings referencing this schedule, the same flexibility principle applies — slower escalation reduces adverse event burden without substantially altering the eventual steady-state pharmacodynamic profile.

SUSTAIN-6 (doi:10.1056/NEJMoa1607141) used a lower maintenance dose of 1.0mg (type 2 diabetes indication), demonstrating that meaningful metabolic effects occur across a dose range — the 2.4mg schedule represents the upper bound studied for weight outcomes specifically.

Lyophilised Semaglutide requires reconstitution with bacteriostatic water (BW) prior to use. The choice of reconstitution volume determines the working concentration and the injection volumes required for each dose increment.

Example: 5mg vial reconstituted with 2.0mL bacteriostatic water
Working concentration: 2.5mg/mL

Dose	Volume at 2.5mg/mL
0.25 mg	0.10 mL (10 units on U100 syringe)
0.5 mg	0.20 mL (20 units)
1.0 mg	0.40 mL (40 units)
1.7 mg	0.68 mL (68 units)
2.4 mg	0.96 mL (96 units)

For reconstitution technique and storage protocols, see the Peptide Reconstitution & Storage Guide. Reconstituted Semaglutide should be stored refrigerated at 2–8°C and used within 4–6 weeks. Bacteriostatic water extends usable life compared to sterile water due to the benzyl alcohol preservative.

Semaglutide's pharmacokinetic profile is central to its once-weekly dosing feasibility. The compound achieves a plasma half-life of approximately 7 days — achieved through C18 fatty diacid acylation at position 26, which promotes albumin binding and substantially reduces renal clearance compared to native GLP-1 (half-life: 1–2 minutes).

Key pharmacokinetic parameters from published data:

• Time to peak concentration (Tmax): 24–72 hours post-injection (median approximately 24 hours)
• Steady-state plasma concentration: reached after 4–5 weeks of weekly dosing
• Half-life: ~7 days (enables once-weekly subcutaneous administration)
• Bioavailability (subcutaneous): approximately 89%
• Plasma protein binding: >99% (albumin)

The slow approach to steady state means that early weeks of a protocol represent a pharmacologically sub-therapeutic period — effects at week 2 are not predictive of week 17 responses. In the STEP programme, maximum weight loss curves continued beyond the 17-week escalation completion, with most participants not reaching nadir until weeks 40–60.

STEP trials administered Semaglutide via subcutaneous injection into the abdomen, thigh, or upper arm. Subcutaneous injection delivers the compound into the adipose layer beneath the dermis, from which it diffuses into systemic circulation. Intramuscular injection accelerates absorption and should be avoided for research protocols modelled on published trial methodology.

Injection site rotation is standard practice across all GLP-1 agonist research protocols. Repeated injection at the same anatomical site can cause localised lipohypertrophy, which alters absorption kinetics and introduces variability into pharmacokinetic measurements. A structured rotation schedule — for example, dividing the abdomen into quadrants and rotating weekly — minimises this confound.

The injection day should remain consistent week-to-week (e.g., always on a Sunday morning) to maintain consistent interdose intervals. GLP-1 agonist pharmacodynamics are influenced by dosing regularity; irregular intervals produce variable trough concentrations and may affect appetite suppression consistency.

Beyond the primary weight outcomes, the STEP programme generated several pharmacodynamic observations relevant to researchers:

• Dose-response relationship: Weight loss was dose-dependent across 0.5mg, 1mg, and 2.4mg cohorts in STEP 2 (type 2 diabetes population), confirming meaningful receptor engagement across the escalation range
• GI adverse event profile: Nausea was reported by ~74% of participants at some point but was predominantly mild-to-moderate and transient — peak incidence occurred during the escalation phase, with substantial improvement by maintenance
• Weight regain on discontinuation: STEP 4 withdrawal data showed ~7% weight regain within 12 months of stopping, with full return to near-baseline by ~65 weeks — confirming the pharmacological nature of weight maintenance
• Cardiovascular signal: SUSTAIN-6 demonstrated 26% reduction in MACE (cardiovascular death, non-fatal MI, non-fatal stroke) versus placebo in a high-risk T2D population

For comprehensive mechanistic detail and full STEP trial outcomes, see the Semaglutide Research Guide. For comparison with Tirzepatide and Retatrutide, see the GLP-1 Peptides Comparison Guide.

All content is for laboratory research reference only. RetaLABS Semaglutide is not for human consumption.